|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, in colon cancer xenograft mice, PHD2 overexpression suppressed tumor growth accompanied by decreased Ki67 expression.
|
31838134 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of tumor tissues using reverse phase protein arrays demonstrates that Phd2 deletion activates the AKT-mTOR-S6 signaling axis in the recovered tumors.
|
30575721 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment of MDA-MB231-derived xenografts with the glucose competitor 2-deoxy-glucose leads to tumor regression in the presence of PHD2.
|
28329677 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After a structural analysis of both binding partners, we suggest that this novel interface is responsible for PHD2 interaction with the LIMD1 tumor suppressor.
|
26754054 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis.
|
26323721 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We show that PHD2 haplodeficiency reduced metastasis via two mechanisms: (1) by decreasing CAF activation, matrix production, and contraction by CAFs, an effect that surprisingly relied on PHD2 deletion in cancer cells, but not in CAFs; and (2) by improving tumor vessel normalization.
|
26235614 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that that high PHD2 expression was significantly associated with higher stage (stages III + IV) (odds ratio [OR] = 5.576, P < 0.001), larger tumor size (> 5 cm) (OR = 6.176, P < 0.001), poorer tumor differentiation (OR = 1.424, P = 0.003), and higher serum alpha fetoprotein (AFP) level (OR = 6.861, P < 0.001).
|
25546659 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This functional comparative study showed that two categories of PHD2 mutants could be distinguished: one category with a weak deficiency in hypoxia inducible factor α regulation and a second one with a deleterious effect; the mutant implicated in tumor occurrence belongs to the second category.
|
21933857 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest that PHD2/HIF-2/amphiregulin signaling has a critical role in the regulation of breast tumor progression and propose PHD2 as a potential tumor suppressor in breast cancer.
|
20856199 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We provide evidence that the suppression of the LDH-A gene leads to an increased level of hypoxia inducible factor 1α (HIF1α) but in consequence not to an increase of HIF1 regulated proteins such as carbonic anhydrase IX (CAIX), vascular endothelial growth factor (VEGF), prolyl-hydroxylase 2 (PHD2), and factor-inhibiting HIF (FIH) in cell cultures and tumor lysates.
|
21660559 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The purpose of the present study was to investigate the relationship of expression of hypoxia inducible factor (HIF)-1α-modifying enzymes prolyl hydroxylase (PHD)1, PHD2 and PHD3 to response of tumours and survival in breast cancer patients enrolled in a phase II trial of neoadjuvant anthracycline and tamoxifen therapy.
|
21291529 |
2011 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
|
19737309 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PHD2 expression was detected in the majority of sarcoma cases, with increased expression correlating with high tumor grade but not with survival.
|
20026900 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RCC tumors with WT VHL had higher levels of Rpb1(OH) and PHD1 and lower levels of PHD2 than tumors with VHL gene alterations.
|
20978146 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, we demonstrate loss of heterozygosity of PHD2 in the tumor, suggesting that PHD2 could be a tumor-suppressor gene.
|
19092153 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, they imply that even the elevated PHD2 levels are not sufficient to down-regulate HIF-1alpha in some tumors.
|
16489060 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, EGLN1 can be considered as a candidate tumor suppressor on chr.
|
16161047 |
2006 |